Company Profile

Astrazeneca Pharma India is currently trading at Rs. 3905.70, up by 314.95 points or 8.77% from its previous closing of Rs. 3590.75 on the BSE.

The scrip opened at Rs. 3735.00 and has touched a high and low of Rs. 3971.00 and Rs. 3713.50 respectively. So far 34234 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4970.00 on 08-Sep-2020 and a 52 week low of Rs. 2540.00 on 22-Apr-2020.

Last one week high and low of the scrip stood at Rs. 3971.00 and Rs. 3410.00 respectively. The current market cap of the company is Rs. 9764.25 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 3.82% and 21.18% respectively.

AstraZeneca Pharma India has launched Fasenra in India. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

Earlier, the company had received Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra).

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Hero MotoCorp and Gogoro Inc. have entered into strategic partnership to accelerate the shift to sustainable electric mobility in India. The partnership brings together the company and Gogoro, the global leader in urban battery swapping and smart mobility innovation.

Maruti Suzuki India's -- Cargo Variants of EECO have been upgraded to new version of Reverse Park Alert Systems (RPAS) system. The revised Ex-showroom price applicable in Delhi shall vary from approximately Rs 4.27 lakh to Rs 5.49 lakh. The same is effective from April 21, 2021.

KEC International has won new orders of Rs 1,245 crore across various businesses. The transmission and distribution business secured orders of Rs 629 crore for projects in India, SAARC, Middle East, Africa and the Americas.

Lupin has incorporated a wholly-owned subsidiary in the USA under the name ‘Lupin Oncology Inc.’ (LOI). This wholly owned subsidiary will be engaged in development/co-development and commercialization of multiple oncology products globally. LOI will be pursuing partners, financial sponsors and perform such other acts as may be necessary.

AstraZeneca Pharma India has launched Fasenra in India. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

LIC Housing Finance’s parent organization -- Life Insurance Corporation (LIC) has collected new premiums of Rs 1.84 lakh crore in FY21. It also paid out Rs 1.34 lakh crore as claims during the year. Despite Coronavirus outbreak where there was a nationwide lockdown imposed during Q1FY21, this is its highest ever new premium collection by LIC.

GE Power India has completed acquisition of 50% of the issued and paid up share capital of NTPC GE Power Services (NGSL) on April 19, 2021. Earlier, the company’s board had approved the acquisition of 50% of the issued and paid-up share capital of NGSL for Rs 7.2 crore. The acquisition of shares of NGSL from GEPower Systems GmbH is a related party transaction as the Company and GE Power Systems GmbH are GE Group Affiliates.

AstraZeneca Pharma India has launched Fasenra in India. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

Earlier, the company had received Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra).

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg film coated tablets (Tagrisso).

Osimertinib 40mg/80mg film coated tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets into a new disease area in India, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.